利福布汀用于治疗利福平耐药结核病患者的潜在应用
研究评估了349名南非和172名比利时利福平耐药结核病(RR-TB)患者的rpoB多态性对利福布汀敏感性的影响,并通过系统综述汇总数据。112种rpoB多态性中,17种可分类为对利福布汀敏感或耐药,11种与利福布汀敏感相关;516GTC突变最常见,占敏感分离株的70%(南非)和76%(比利时)。在南非和比利时RR-TB患者中,这11种多态性分别占33.2%和16.6%,提示部分患者可能受益于含利福布汀方案,但需随机对照试验提供政策改变证据。
要点
- 112种rpoB多态性中,17种可分类利福布汀敏感性,11种与敏感相关。
- 516GTC突变占利福布汀敏感分离株的70%(南非)和76%(比利时)。
- 11种敏感相关多态性在南非和比利时RR-TB患者中分别占33.2%和16.6%。
核心结论
- 鉴定导致RR-TB诊断的精确rpoB多态性,有可能使相当比例的RR-TB患者接受含利福布汀的治疗方案。
- 需要一项随机对照试验评估含利福布汀方案在这些选定患者中的疗效,以提供改变政策所需的证据。
研究设计与样本
- 研究评估了来自南非的349名个体和来自比利时的172名个体的rpoB突变对利福布汀的敏感性。
- 通过Sanger测序鉴定rpoB多态性,并表型评估利福平和利福布汀敏感性。
- 进行了系统综述以全面汇总关于rpoB多态性对利福布汀敏感性的信息。
- 基于阳性似然比和OR值将利福布汀敏感性分配给rpoB多态性。
主要发现
- 从全部2045名RR-TB患者中鉴定出112种rpoB多态性(67.9%来自文献),其中17种可分类为对利福布汀敏感或耐药。
- 11种多态性与利福布汀敏感性相关。
- 516GTC突变是最常见的,占所有利福布汀敏感分离株的70%(南非)和76%(比利时)。
- 在人群水平,与利福布汀敏感性相关的11种多态性分别出现在33.2%的南非和16.6%的比利时诊断为RR-TB的患者中。
关键数值与推荐
- 利福布汀敏感性基于rpoB多态性的阳性似然比和OR值进行分配。
- 112种rpoB多态性中,17种可分类为对利福布汀敏感或耐药。
- 11种多态性与利福布汀敏感性相关。
- 516GTC突变占利福布汀敏感分离株的70%(南非)和76%(比利时)。
- 11种利福布汀敏感相关多态性在南非和比利时RR-TB患者中分别占33.2%和16.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Use of the Xpert MTB/RIF assay has increased the number of people diagnosed with rifampicin-resistant tuberculosis (RR-TB), especially in South Africa where Xpert is now the initial diagnostic for individuals with TB symptoms. We hypothesized that a proportion of RR-TB patients determined by Xpert can be treated with a rifabutin-containing regimen. METHODS: Rifabutin susceptibility by rpoB mutation was assessed in 349 individuals from South Africa and 172 from Belgium. rpoB polymorphisms were identified by Sanger sequencing. Rifampicin and rifabutin susceptibility was assessed phenotypically. A systematic review was performed to comprehensively collate information on rifabutin susceptibility by rpoB polymorphism. Rifabutin susceptibility was assigned to rpoB polymorphisms based on their positive likelihood ratios and ORs. RESULTS: One hundred and twelve rpoB polymorphisms (67.9% from literature) were identified from all 2045 RR-TB patients, of which 17 polymorphisms could be classified as susceptible/resistant to rifabutin. Eleven polymorphisms were associated with rifabutin susceptibility. The 516GTC mutation was the most common, representing 70% (South Africa) and 76% (Belgium) of all rifabutin-susceptible isolates. At a population level, the 11 polymorphisms associated with rifabutin susceptibility occurred in 33.2% and 16.6% of all South African and Belgian patients diagnosed with RR-TB, respectively. CONCLUSIONS: Identification of the exact rpoB polymorphism leading to the diagnosis of RR-TB has the potential to allow inclusion of rifabutin in the treatment regimen of a substantial proportion of RR-TB patients. A randomized controlled trial evaluating the efficacy of a rifabutin-containing TB treatment regimen in these selected patients is needed to provide the evidence required for a change in policy.
引用
- Whitfield MG, Warren RM, Mathys V, et al. The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother. 2018. PMID: 29982641. doi:10.1093/jac/dky248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。